Health Care & Life Sciences » Pharmaceuticals | Hisamitsu Pharmaceutical Co. Inc.

Hisamitsu Pharmaceutical Co. Inc. | Ownership

Companies that own Hisamitsu Pharmaceutical Co. Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
The Vanguard Group, Inc.
1,779,010
1.87%
17,288
0%
07/31/2018
Nomura Asset Management Co., Ltd.
1,115,899
1.17%
22,617
0.05%
07/31/2018
BlackRock Fund Advisors
1,014,900
1.07%
-600
0%
09/06/2018
Norges Bank Investment Management
796,699
0.84%
-268,736
0.01%
12/31/2017
Daiwa Asset Management Co. Ltd.
543,000
0.56%
11,200
0.05%
07/31/2018
Nikko Asset Management Co., Ltd.
466,299
0.49%
-3,201
0.02%
09/03/2018
JF Asset Management Ltd.
245,900
0.26%
99,400
0.08%
06/30/2018
BlackRock Advisors (UK) Ltd.
223,864
0.24%
2,100
0.01%
09/06/2018
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.
222,200
0.23%
42,100
0.04%
04/01/2018
Geode Capital Management LLC
201,600
0.21%
4,400
0%
09/11/2018

About Hisamitsu Pharmaceutical Co.

View Profile
Address
408 Tashiro Daikan-machi
Tosu Saga 841
Japan
Employees -
Website http://www.hisamitsu.co.jp
Updated 07/08/2019
Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, Lifecella, and Keplat brands. It also provides ethical pharmaceuticals, over the counter drugs, medical devices, health supplements, and topical analgesic products.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.